Results 251 to 260 of about 12,584 (301)
Some of the next articles are maybe not open access.
Drugs of Today, 2021
Cardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol
C E, Kosmas +3 more
openaire +2 more sources
Cardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol
C E, Kosmas +3 more
openaire +2 more sources
Annals of Internal Medicine, 2010
Dyslipidemia is an important risk factor for coronary artery disease and stroke. Long-term, prospective epidemiologic studies have consistently shown that persons with healthier lifestyles and fewer risk factors for coronary heart disease, and particularly those with favorable lipid profiles, have reduced incidence of coronary heart disease. Prevention
Laurie, Kopin, Charles, Lowenstein
openaire +2 more sources
Dyslipidemia is an important risk factor for coronary artery disease and stroke. Long-term, prospective epidemiologic studies have consistently shown that persons with healthier lifestyles and fewer risk factors for coronary heart disease, and particularly those with favorable lipid profiles, have reduced incidence of coronary heart disease. Prevention
Laurie, Kopin, Charles, Lowenstein
openaire +2 more sources
Current Treatment Options in Cardiovascular Medicine, 2001
The major goal in treatment of patients with dyslipidemia is to decrease the short- and long-term incidence of cardiovascular events, including myocardial infarction, unstable angina, stroke, and death. A second goal in patients with severe hypertriglyceridemia is to decrease the risk of acute pancreatitis.
Adam M., Cohen, Daniel J., Rader
openaire +2 more sources
The major goal in treatment of patients with dyslipidemia is to decrease the short- and long-term incidence of cardiovascular events, including myocardial infarction, unstable angina, stroke, and death. A second goal in patients with severe hypertriglyceridemia is to decrease the risk of acute pancreatitis.
Adam M., Cohen, Daniel J., Rader
openaire +2 more sources
Endocrinology and Metabolism Clinics of North America, 2015
"Recent studies have revealed evidence that poorly controlled cholesterol, triglycerides, and their metabolites during pregnancy may be associated with cardiometabolic dysfunction and have significant detrimental fetal and maternal vascular consequences.
Robert, Wild +2 more
openaire +3 more sources
"Recent studies have revealed evidence that poorly controlled cholesterol, triglycerides, and their metabolites during pregnancy may be associated with cardiometabolic dysfunction and have significant detrimental fetal and maternal vascular consequences.
Robert, Wild +2 more
openaire +3 more sources
Contraception, 2016 ContextDyslipidemias represent a spectrum of lipid disorders that are important risk factors for cardiovascular disease. In addition, elevated triglycerides are known to be associated with pancreatitis.
Mónica Dragoman +2 more
exaly +2 more sources
Current Diabetes Reports, 2001
Numerous prospective cohort studies have indicated that diabetes mellitus (DM), particularly type-2 DM (the type of diabetes associated with insulin resistance that usually strikes adults), is associated with a 3-4-fold increase in risk for coronary heart disease (CHD) [1-3].
H N, Ginsberg, C, Tuck
openaire +3 more sources
Numerous prospective cohort studies have indicated that diabetes mellitus (DM), particularly type-2 DM (the type of diabetes associated with insulin resistance that usually strikes adults), is associated with a 3-4-fold increase in risk for coronary heart disease (CHD) [1-3].
H N, Ginsberg, C, Tuck
openaire +3 more sources
APOE genotypes and dyslipidemias in a sample of the Portuguese population [PDF]
Clinical Chemistry and Laboratory Medicine, 2005 The objective of this work was to study the distribution of apolipoprotein E (APOE) genotypes in a sample of the Portuguese population, and its association with the dyslipidemias observed.
CARLOS Matias Dias
exaly +2 more sources
Endocrinology and Metabolism Clinics of North America, 2008
The alarming and still increasing prevalence of obesity and associated cardiovascular risk raises much concern. The increase in cardiovascular risk depends to a significant extent on the changes in lipid profiles as observed in obesity. These changes are decreased high-density lipoprotein cholesterol and increased triglyceride levels.
Franssen, Remco +3 more
openaire +3 more sources
The alarming and still increasing prevalence of obesity and associated cardiovascular risk raises much concern. The increase in cardiovascular risk depends to a significant extent on the changes in lipid profiles as observed in obesity. These changes are decreased high-density lipoprotein cholesterol and increased triglyceride levels.
Franssen, Remco +3 more
openaire +3 more sources
Endocrinology and Metabolism Clinics of North America, 2006
Type 2 diabetes mellitus is associated with a markedly increased risk of cardiovascular disease. A complex dyslipidemia, which is an integral part of the underlying insulin resistance in this group, is a key to this increased risk. Increased secretion of VLDL from the liver is a central feature of dyslipidemia and is linked significantly to the low HDL
Tina J, Chahil, Henry N, Ginsberg
openaire +2 more sources
Type 2 diabetes mellitus is associated with a markedly increased risk of cardiovascular disease. A complex dyslipidemia, which is an integral part of the underlying insulin resistance in this group, is a key to this increased risk. Increased secretion of VLDL from the liver is a central feature of dyslipidemia and is linked significantly to the low HDL
Tina J, Chahil, Henry N, Ginsberg
openaire +2 more sources
Nursing Clinics of North America, 2023
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. The development and progression of atherosclerotic CVD are largely dependent on a multitude of modifiable and nonmodifiable risk factors. Current therapeutic strategies involve risk factor modification, especially dyslipidemia.
Jennifer, Ballard-Hernandez, James, Sall
openaire +2 more sources
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. The development and progression of atherosclerotic CVD are largely dependent on a multitude of modifiable and nonmodifiable risk factors. Current therapeutic strategies involve risk factor modification, especially dyslipidemia.
Jennifer, Ballard-Hernandez, James, Sall
openaire +2 more sources